MedPath

Impact of Hyperoxia During Cardiopulmonary

Phase 3
Completed
Conditions
Cardiac Complications
Interventions
Registration Number
NCT02819739
Lead Sponsor
Centre Hospitalier Universitaire, Amiens
Brief Summary

The hypothesis implies that this work is the use of hyperoxia during cardiopulmonary bypass by his heart preconditioning effect is associated with a lower incidence of cardiac arrhythmias (atrial fibrillation, tachycardia or ventricular fibrillation) and lesions of myocardial ischemia-reperfusion injury in cardiac surgery postoperative.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
330
Inclusion Criteria
  • Major patient ≥ 18 years
  • Patient operated cardiac surgery for myocardial revascularization (CABG) or surgical correction of valvular or combined surgery (CABG and valve disease) or ascending aortic surgery
  • Signed Consent
  • Affiliation to social security
Exclusion Criteria
  • Permanent atrial fibrillation
  • Cordarone therapy,
  • Pregnant woman
  • Patient under guardianship or trusteeship or private public law
  • Internal pacemaker
  • Hypothermia,
  • Patient refusal,
  • Cardiac surgery without extracorporal circulation (ECC),
  • Participation in another study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
normoxiamedical oxygenDuring cardiopulmonary bypass inspired fraction of oxygen is adapted to maintained a oxygen arterial pressure below 150 mmHg.
hyperoxiamedical oxygenDuring cardiopulmonary bypass inspired fraction of oxygen is set to 100 %.
Primary Outcome Measures
NameTimeMethod
Occurred within 15 days after surgery, disorders of heart rhythm (atrial fibrillation, tachycardia or ventricular fibrillation)15 days after surgery
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

CHU Dijon-Bourgogne

🇫🇷

Dijon, France

CHU Amiens-Picardie

🇫🇷

Amiens, France

© Copyright 2025. All Rights Reserved by MedPath